newsfilter
← Latest News
GlobeNewswire·

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest